Rona Z Silkiss, MD
Ophthalmology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 23
- 6 carriers
- Offices
- 8
Offices
8 locations · North Bay Eye Associates, A Medical Corporation · Eye Care Center of Napa Valley A Medical Corporation
Hospitals listed: Alta Bates Summit Medical Center · California Pacific Medical Ctr-Davies Campus Hosp · John Muir Medical Center - Walnut Creek Campus. That is not proof they admit you there this week.
Plans that list them
23 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Silkiss’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
23 of 23 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G45822 · Current
Licensed to practise in California · since 1981 · expires 2028-10-31 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Aspen Surgery Center, LLC dba Aspen Surgery CenterAmbulatory Surgery Center · Walnut Creek, CA1.55% owner since 2008 · accredited by AAAHCAccreditation Renewed6 inspections, 1 with deficiencies · last 2024-07-15
- Aspen Surgery Center, LLC- Walnut CreekAmbulatory Surgery Center · Walnut Creek, CA1.55% owner since 2008 · accredited by AAAHCAccreditation Renewed2 inspections, 1 with deficiencies · last 2024-07-15
- The Surgery Center of Alta Bates Summit Medical CenterAmbulatory Surgery Center · Oakland, CAOwner · accredited by JCInitial Accreditation4 inspections, 4 with deficiencies · last 2017-07-27: Requirements Met
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$601,323
Medicare paid this office $601,323 for 1,120 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of excessive skin and fat of upper eyelid | 135 | $110,871 | $821 |
| New patient visit (45+ min) | 655 | $101,898 | $156 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 112 | $57,627 | $510 |
| Botox | 45 | $49,273 | None |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 33 | $30,289 | $797 |
See all 22 services
| Removal of excessive skin and fat of upper eyelid | 135 | $110,871 | $821 |
| New patient visit (45+ min) | 655 | $101,898 | $156 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 112 | $57,627 | $510 |
| Botox | 45 | $49,273 | None |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 33 | $30,289 | $797 |
| Short return visit (20+ min) | 266 | $26,867 | $86 |
| Removal of growth of eyelid | 81 | $24,621 | $293 |
| Repair of tendon of upper eyelid | 31 | $22,908 | $694 |
| Extensive repair of turning-outward eyelid defect | 49 | $20,059 | $378 |
| Incision of tear duct using an endoscope | 26 | $16,683 | $618 |
| Face injection for nerve paralysis | 45 | $14,577 | $140 |
| Extensive repair of turning-inward eyelid defect | 26 | $13,647 | $471 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 17 | $13,179 | $694 |
| Return visit (30+ min) | 95 | $12,305 | $116 |
| Short return visit | 139 | $11,394 | $55 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 22 | $9,156 | $381 |
| Probing of nasal tear duct | 53 | $7,827 | $142 |
| Photography of content of eyes | 293 | $7,351 | $25 |
| Exam of visual field with intermediate testing | 101 | $4,688 | $46 |
| Probing of nasal tear duct with insertion of tube or stent | 35 | $4,423 | $120 |
| Removal of chronic eyelid growth under general anesthesia and/or requiring hospitalization | 15 | $3,652 | $243 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 13 | $1,470 | $98 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 44 | More than 85% of doctors who do this |
Who their Medicare patients are
1,120 Original Medicare patients in 2024. Average age 76 · Under 65 2% · 85 and older 13% · Women 66% · Also on Medicaid 12% · Health risk score 1.01. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 66% · Coronary heart disease 22% · Diabetes 21% · Chronic kidney disease 18% · Depression 18% · Atrial fibrillation 16% · Cancer 15% · COPD 10% · Heart failure 9% · Stroke 6% · Dementia 3%.
The office billed $1,490,771, Medicare allowed $765,583 and paid $601,323; for 12,842 services of 56 kinds; $49,558 of it was for drugs given in the office and $551,765 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,120 | 12,842 | 76 | 1.01 | $1,490,771 | $601,323 |
| 2023 | 1,109 | 12,109 | 76 | 0.98 | $1,390,877 | $540,052 |
| 2022 | 993 | 10,811 | 76 | 0.93 | $1,288,813 | $467,291 |
| 2021 | 1,018 | 12,772 | 76 | 0.98 | $1,377,221 | $520,278 |
| 2020 | 727 | 10,508 | 76 | 1.03 | $1,377,508 | $351,628 |
| 2019 | 1,015 | 13,061 | 76 | 1.07 | $2,213,193 | $493,398 |
| 2018 | 999 | 14,748 | 76 | 1.15 | $1,779,223 | $458,268 |
| 2017 | 1,087 | 10,825 | 76 | 1.08 | $1,758,842 | $426,629 |
| 2016 | 1,076 | 12,529 | 76 | 1.12 | $2,047,815 | $497,227 |
| 2015 | 1,038 | 9,298 | 76 | 1.06 | $1,925,111 | $478,350 |
| 2014 | 904 | 8,696 | 76 | 1.00 | $1,502,730 | $417,107 |
| 2013 | 826 | 8,118 | 75 | 1.01 | $1,407,898 | $380,194 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| New patient visit (45+ min) | 742 | $106,926 | $144 |
| Removal of excessive skin and fat of upper eyelid | 129 | $103,954 | $806 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 100 | $48,910 | $484 |
| Botox | 39 | $46,679 | None |
| Removal of growth of eyelid | 88 | $26,405 | $284 |
| Short return visit (20+ min) | 231 | $23,227 | $80 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 26 | $20,664 | $765 |
| Extensive repair of turning-outward eyelid defect | 42 | $18,106 | $421 |
| Repair of tendon of upper eyelid | 20 | $13,117 | $625 |
| Face injection for nerve paralysis | 40 | $12,940 | $133 |
| Incision of tear duct using an endoscope | 22 | $12,904 | $561 |
| Return visit (30+ min) | 90 | $10,859 | $109 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 17 | $10,823 | $601 |
| Short return visit | 146 | $10,327 | $50 |
| Extensive repair of turning-inward eyelid defect | 22 | $10,108 | $421 |
| Photography of content of eyes | 333 | $7,530 | $22 |
| Probing of nasal tear duct | 50 | $6,934 | $131 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 12 | $4,461 | $372 |
| Probing of nasal tear duct with insertion of tube or stent | 31 | $3,859 | $117 |
| Removal of chronic eyelid growth under general anesthesia and/or requiring hospitalization | 13 | $3,770 | $269 |
| Exam of visual field with intermediate testing | 64 | $2,791 | $44 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 14 | $1,210 | $86 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $11 | None |
2022: 20 services
| Removal of excessive skin and fat of upper eyelid | 127 | $94,211 | $742 |
| New patient visit (45+ min) | 654 | $89,808 | $137 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 91 | $41,343 | $454 |
| Botox | 38 | $39,926 | None |
| Short return visit (20+ min) | 278 | $27,014 | $77 |
| Removal of growth of eyelid | 61 | $18,183 | $280 |
| Extensive repair of turning-outward eyelid defect | 32 | $13,667 | $427 |
| Repair of tendon of upper eyelid | 21 | $13,533 | $644 |
| Incision of tear duct using an endoscope | 21 | $12,570 | $547 |
| Face injection for nerve paralysis | 38 | $11,024 | $130 |
| Extensive repair of turning-inward eyelid defect | 26 | $10,942 | $405 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 15 | $9,181 | $612 |
| Short return visit | 118 | $8,004 | $45 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 13 | $7,859 | $605 |
| Probing of nasal tear duct | 58 | $7,804 | $124 |
| Return visit (30+ min) | 67 | $7,484 | $110 |
| Photography of content of eyes | 270 | $6,004 | $22 |
| Probing of nasal tear duct with insertion of tube or stent | 33 | $3,893 | $111 |
| Exam of visual field with intermediate testing | 57 | $2,552 | $43 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 14 | $1,174 | $84 |
2021: 23 services
| New patient visit (45+ min) | 717 | $104,300 | $145 |
| Removal of excessive skin and fat of upper eyelid | 93 | $72,239 | $777 |
| Botox | 43 | $48,951 | None |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 75 | $32,308 | $420 |
| Short return visit (20+ min) | 276 | $29,975 | $82 |
| Removal of growth of eyelid | 88 | $28,878 | $286 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 32 | $21,779 | $660 |
| Repair of tendon of upper eyelid | 26 | $17,881 | $662 |
| Extensive repair of turning-outward eyelid defect | 43 | $16,634 | $387 |
| Extensive repair of turning-inward eyelid defect | 36 | $16,264 | $452 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 21 | $14,310 | $681 |
| Face injection for nerve paralysis | 43 | $13,621 | $132 |
| Short return visit | 152 | $11,945 | $51 |
| Incision of tear duct using an endoscope | 21 | $11,748 | $559 |
| Probing of nasal tear duct | 53 | $7,154 | $132 |
| Photography of content of eyes | 281 | $6,767 | $24 |
| Return visit (30+ min) | 56 | $6,718 | $116 |
| Probing of nasal tear duct with insertion of tube or stent | 39 | $5,220 | $134 |
| Tightening of tendon of outer edge of lower eyelid | 20 | $4,465 | $223 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 30 | $2,578 | $86 |
| Exam of visual field with intermediate testing | 43 | $1,982 | $46 |
| Removal of chronic growth of eyelid | 11 | $1,590 | $122 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $14 | None |
2020: 20 services
| Removal of excessive skin and fat of upper eyelid | 78 | $60,530 | $776 |
| New patient visit (45+ min) | 445 | $60,508 | $136 |
| Botox | 38 | $41,741 | None |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 45 | $19,365 | $421 |
| Short return visit (20+ min) | 199 | $17,885 | $66 |
| Repair of tendon of upper eyelid | 25 | $17,518 | $701 |
| Removal of growth of eyelid | 56 | $16,307 | $276 |
| Extensive repair of turning-outward eyelid defect | 27 | $11,911 | $441 |
| Face injection for nerve paralysis | 38 | $11,803 | $130 |
| Incision of tear duct using an endoscope | 17 | $10,348 | $575 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 15 | $9,691 | $646 |
| Extensive repair of turning-inward eyelid defect | 20 | $8,605 | $430 |
| Short return visit | 121 | $7,140 | $39 |
| Probing of nasal tear duct | 37 | $5,106 | $128 |
| Return visit (30+ min) | 45 | $4,334 | $92 |
| Probing of nasal tear duct with insertion of tube or stent | 27 | $3,823 | $123 |
| Photography of content of eyes | 132 | $2,949 | $22 |
| Tightening of tendon of outer edge of lower eyelid | 11 | $2,308 | $210 |
| New patient visit (30+ min) | 16 | $1,414 | $88 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 14 | $1,213 | $87 |
2019: 25 services
| New patient visit (45+ min) | 594 | $80,924 | $136 |
| Removal of excessive skin and fat of upper eyelid | 89 | $64,243 | $722 |
| Botox | 47 | $49,803 | None |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 90 | $41,653 | $458 |
| Repair of tendon of upper eyelid | 38 | $24,958 | $624 |
| Creation of drainage tract from tear sac to nasal cavity | 29 | $20,959 | $723 |
| Extensive repair of turning-outward eyelid defect | 48 | $19,194 | $400 |
| Removal of growth of eyelid | 61 | $17,217 | $273 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 21 | $17,104 | $744 |
| Short return visit (20+ min) | 186 | $16,999 | $66 |
| Return visit (30+ min) | 144 | $16,872 | $95 |
| Extensive repair of turning-inward eyelid defect | 36 | $15,720 | $437 |
| Face injection for nerve paralysis | 46 | $13,627 | $125 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 19 | $12,657 | $666 |
| Short return visit | 116 | $6,826 | $38 |
| Probing of nasal tear duct | 43 | $5,915 | $129 |
| Probing of nasal tear duct with insertion of tube or stent | 45 | $5,753 | $122 |
| Exam of visual field with extended testing | 90 | $5,723 | $62 |
| Correction of widely-opened upper eyelid | 11 | $4,807 | $437 |
| Photography of content of eyes | 218 | $4,493 | $21 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 11 | $4,387 | $366 |
| Established patient problem focused exam of visual system | 45 | $3,180 | $71 |
| New patient visit (60+ min) | 16 | $2,530 | $158 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 16 | $1,365 | $85 |
| Exam of visual field with limited testing | 14 | $190 | $14 |
2018: 23 services
| New patient visit (45+ min) | 580 | $76,596 | $132 |
| Botox | 51 | $58,129 | None |
| Removal of excessive skin and fat of upper eyelid | 56 | $39,511 | $706 |
| Repair of tendon of upper eyelid | 54 | $35,823 | $663 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 57 | $26,598 | $459 |
| Creation of drainage tract from tear sac to nasal cavity | 29 | $23,019 | $677 |
| Removal of growth of eyelid | 77 | $21,236 | $250 |
| Short return visit (20+ min) | 257 | $20,698 | $61 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 24 | $18,918 | $757 |
| Extensive repair of turning-outward eyelid defect | 45 | $18,334 | $390 |
| Face injection for nerve paralysis | 51 | $14,897 | $120 |
| Extensive repair of turning-inward eyelid defect | 27 | $11,937 | $426 |
| Return visit (30+ min) | 123 | $11,470 | $86 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 19 | $11,394 | $600 |
| Probing of nasal tear duct | 59 | $8,335 | $121 |
| Short return visit | 139 | $7,288 | $37 |
| Probing of nasal tear duct with insertion of tube or stent | 40 | $5,015 | $117 |
| Photography of content of eyes | 245 | $4,809 | $19 |
| Exam of visual field with extended testing | 76 | $4,617 | $59 |
| Established patient problem focused exam of visual system | 30 | $2,320 | $75 |
| New patient visit (60+ min) | 13 | $2,244 | $173 |
| Removal of chronic growth of eyelid | 13 | $1,628 | $109 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 12 | $1,289 | $107 |
2017: 24 services
| New patient visit (45+ min) | 663 | $82,749 | $125 |
| Removal of excessive skin and fat of upper eyelid | 69 | $47,114 | $683 |
| Botox | 41 | $38,082 | None |
| Repair of tendon of upper eyelid | 46 | $31,349 | $667 |
| Short return visit (20+ min) | 262 | $19,601 | $57 |
| Removal of growth of eyelid | 73 | $19,323 | $239 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 39 | $17,151 | $440 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 22 | $17,057 | $711 |
| Return visit (30+ min) | 134 | $13,951 | $88 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 22 | $13,770 | $626 |
| Extensive repair of turning-outward eyelid defect | 39 | $13,770 | $344 |
| Creation of drainage tract from tear sac to nasal cavity | 18 | $11,795 | $655 |
| Face injection for nerve paralysis | 39 | $9,582 | $115 |
| Extensive repair of turning-inward eyelid defect | 20 | $8,470 | $424 |
| Photography of content of eyes | 318 | $5,975 | $19 |
| Short return visit | 103 | $5,310 | $35 |
| Probing of nasal tear duct | 43 | $5,245 | $114 |
| Exam of visual field with extended testing | 70 | $4,235 | $58 |
| Probing of nasal tear duct with insertion of tube or stent | 29 | $3,445 | $111 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 19 | $2,236 | $118 |
| Established patient problem focused exam of visual system | 27 | $1,822 | $63 |
| Probing of nasal tear duct | 15 | $1,516 | $101 |
| New patient visit (30+ min) | 15 | $811 | $54 |
| Exam of visual field with limited testing | 24 | $288 | $12 |
2016: 25 services
| New patient visit (45+ min) | 606 | $81,123 | $134 |
| Removal of excessive skin and fat of upper eyelid | 92 | $64,888 | $705 |
| Botox | 41 | $45,312 | None |
| Repair of tendon of upper eyelid | 45 | $30,958 | $688 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 58 | $27,421 | $465 |
| Extensive repair of turning-outward eyelid defect | 58 | $24,367 | $393 |
| Creation of drainage tract from tear sac to nasal cavity | 30 | $22,685 | $687 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 26 | $22,023 | $759 |
| Short return visit (20+ min) | 250 | $18,501 | $61 |
| Removal of growth of eyelid | 64 | $17,389 | $248 |
| Extensive repair of turning-inward eyelid defect | 37 | $16,860 | $444 |
| Return visit (30+ min) | 181 | $16,705 | $83 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 24 | $15,214 | $634 |
| Face injection for nerve paralysis | 42 | $12,205 | $115 |
| Photography of content of eyes | 311 | $6,002 | $19 |
| Probing of nasal tear duct | 49 | $5,961 | $117 |
| Correction of widely-opened upper eyelid | 13 | $4,982 | $383 |
| Probing of nasal tear duct with insertion of tube or stent | 40 | $4,974 | $113 |
| Short return visit | 99 | $4,441 | $36 |
| New patient visit (30+ min) | 28 | $2,526 | $90 |
| Established patient problem focused exam of visual system | 35 | $2,338 | $65 |
| Probing of nasal tear duct | 15 | $1,658 | $111 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 15 | $1,611 | $107 |
| Exam of visual field with extended testing | 20 | $1,252 | $57 |
| Exam of visual field with limited testing | 19 | $271 | $14 |
2015: 26 services
| New patient visit (45+ min) | 603 | $83,199 | $138 |
| Removal of excessive skin and fat of upper eyelid | 75 | $53,639 | $715 |
| Repair of tendon of upper eyelid | 58 | $39,354 | $645 |
| Botox | 38 | $30,021 | None |
| Creation of drainage tract from tear sac to nasal cavity | 37 | $28,425 | $677 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 48 | $22,827 | $466 |
| Extensive repair of turning-outward eyelid defect | 54 | $21,867 | $390 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 28 | $21,148 | $755 |
| Insertion of probe into nasal tear duct | 73 | $17,963 | $233 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 24 | $15,724 | $655 |
| Short return visit (20+ min) | 209 | $15,422 | $58 |
| Return visit (30+ min) | 138 | $14,682 | $95 |
| Extensive repair of turning-inward eyelid defect | 30 | $13,590 | $453 |
| Removal of growth of eyelid | 48 | $13,552 | $246 |
| Face injection for nerve paralysis | 37 | $9,986 | $116 |
| Probing of nasal tear duct with insertion of tube or stent | 50 | $7,388 | $134 |
| Short return visit | 128 | $6,158 | $36 |
| Photography of content of eyes | 260 | $5,131 | $20 |
| Established patient problem focused exam of visual system | 57 | $4,234 | $69 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 16 | $2,021 | $126 |
| New patient visit (30+ min) | 23 | $1,745 | $76 |
| Probing of nasal tear duct | 11 | $1,258 | $114 |
| Established patient complete exam of visual system | 12 | $1,113 | $93 |
| Exam of visual field with extended testing | 16 | $906 | $57 |
| Exam of visual field with limited testing | 22 | $777 | $32 |
| Removal of eyelashes using forceps | 11 | $600 | $43 |
2014: 22 services
| New patient visit (45+ min) | 455 | $61,133 | $134 |
| Removal of excessive skin and fat of upper eyelid | 61 | $44,547 | $730 |
| Repair of tendon of upper eyelid | 47 | $34,090 | $725 |
| Botox | 44 | $28,176 | None |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 54 | $27,115 | $493 |
| Creation of drainage tract from tear sac to nasal cavity | 30 | $21,308 | $687 |
| Extensive repair of turning-outward eyelid defect | 43 | $17,839 | $415 |
| Insertion of probe into nasal tear duct | 66 | $17,249 | $243 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 26 | $16,885 | $649 |
| Short return visit (20+ min) | 208 | $14,783 | $61 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 19 | $13,347 | $702 |
| Removal of growth of eyelid | 46 | $12,596 | $247 |
| Extensive repair of turning-inward eyelid defect | 25 | $10,847 | $434 |
| Face injection for nerve paralysis | 44 | $9,943 | $118 |
| Short return visit | 170 | $8,093 | $38 |
| Return visit (30+ min) | 74 | $7,361 | $93 |
| New patient visit (30+ min) | 69 | $5,906 | $86 |
| Photography of content of eyes | 214 | $4,263 | $20 |
| Probing of nasal tear duct with insertion of tube or stent | 27 | $3,715 | $138 |
| Established patient problem focused exam of visual system | 44 | $2,491 | $57 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 24 | $2,003 | $83 |
| Exam of visual field with extended testing | 29 | $1,745 | $60 |
2013: 25 services
| Removal of excessive skin and fat of upper eyelid | 74 | $55,350 | $748 |
| New patient visit (45+ min) | 343 | $49,190 | $143 |
| Repair of tendon of upper eyelid | 39 | $27,080 | $660 |
| Botox | 43 | $26,309 | None |
| Extensive repair of turning-outward eyelid defect | 48 | $20,251 | $405 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 27 | $20,193 | $748 |
| Removal of tissue, muscle, and membrane to correct eyelid drooping or paralysis | 39 | $19,390 | $485 |
| Insertion of probe into nasal tear duct | 53 | $13,732 | $233 |
| Removal of growth of cavity behind eye | 18 | $13,631 | $757 |
| Short return visit (20+ min) | 180 | $13,029 | $62 |
| Removal of growth of eyelid | 48 | $12,588 | $233 |
| Creation of drainage tract from tear sac to nasal cavity | 17 | $11,887 | $699 |
| Face injection for nerve paralysis | 42 | $11,102 | $122 |
| Reconstruction of up to 2/3 of eyelid with tissue from opposite eyelid | 19 | $11,024 | $580 |
| New patient visit (30+ min) | 82 | $7,480 | $91 |
| Extensive repair of turning-inward eyelid defect | 16 | $6,605 | $413 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 13 | $5,453 | $419 |
| Return visit (30+ min) | 53 | $4,850 | $90 |
| Photography of content of eyes | 194 | $3,895 | $20 |
| Short return visit | 95 | $3,816 | $36 |
| Established patient problem focused exam of visual system | 52 | $3,721 | $69 |
| Probing of nasal tear duct with insertion of tube or stent | 17 | $3,198 | $178 |
| Exam of visual field with extended testing | 40 | $2,181 | $55 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 14 | $1,222 | $87 |
| New patient visit (15+ min) | 11 | $713 | $65 |
Drugs they prescribed that Part D paid
$36,353
Pharmacies billed $36,353 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
908 generic and 114 brand-name prescriptions · $36,353 in drug cost · 107 antibiotic prescriptions to 81 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 18 | $12,880 | $716 |
| Tobramycin-Dexamethasone | 165 | $6,163 | $37 |
| Erythromycin | 474 | $4,638 | $10 |
| Tobradex | 16 | $4,163 | $260 |
| Neomycin-Polymyxin-Dexameth | 78 | $934 | $12 |
See all 10 drugs
| Restasis | 18 | $12,880 | $716 |
| Tobramycin-Dexamethasone | 165 | $6,163 | $37 |
| Erythromycin | 474 | $4,638 | $10 |
| Tobradex | 16 | $4,163 | $260 |
| Neomycin-Polymyxin-Dexameth | 78 | $934 | $12 |
| Fluticasone Propionate | 60 | $856 | $14 |
| Doxycycline Hyclate | 88 | $769 | $9 |
| Clarithromycin | 13 | $352 | $27 |
| Montelukast | 15 | $327 | $22 |
| Polymyxin B Sul-Trimethoprim | 24 | $151 | $6 |
Year by year
| 2024 | 1,022 | 614 | None | 11% | $36,353 |
| 2023 | 900 | 552 | None | None | $53,475 |
| 2022 | 888 | 567 | None | None | $39,218 |
| 2021 | 760 | 441 | 2% (15) | 20% | $44,725 |
| 2020 | 632 | 356 | 4% (24) | 22% | $44,311 |
| 2019 | 684 | 404 | 5% (35) | 27% | $49,580 |
| 2018 | 693 | 360 | 5% (32) | 27% | $46,596 |
| 2017 | 821 | 453 | 18% (151) | 27% | $50,533 |
| 2016 | 936 | 477 | 25% (233) | 23% | $51,032 |
| 2015 | 971 | 454 | 22% (217) | 28% | $63,563 |
| 2014 | 937 | 425 | 23% (219) | 27% | $59,212 |
| 2013 | 779 | 378 | 30% (232) | None | $59,867 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Restasis | 22 | $19,494 | $886 |
| Tobramycin-Dexamethasone | 144 | $7,165 | $50 |
| Tobradex | 20 | $5,583 | $279 |
| Erythromycin | 405 | $4,321 | $11 |
| Doxycycline Hyclate | 72 | $1,202 | $17 |
| Fluticasone Propionate | 58 | $1,042 | $18 |
| Neomycin-Polymyxin-Dexameth | 46 | $669 | $15 |
| Montelukast | 15 | $250 | $17 |
2022: 10 drugs
| Tobramycin-Dexamethasone | 131 | $9,940 | $76 |
| Erythromycin | 408 | $4,183 | $10 |
| Tobradex | 11 | $3,258 | $296 |
| Neomycin-Polymyxin-Dexameth | 97 | $1,402 | $14 |
| Doxycycline Hyclate | 48 | $627 | $13 |
| Fluticasone Propionate | 58 | $608 | $10 |
| Azelastine | 11 | $513 | $47 |
| Montelukast | 15 | $274 | $18 |
| Methylprednisolone | 11 | $121 | $11 |
| Polymyxin B Sul-Trimethoprim | 11 | $79 | $7 |
2021: 9 drugs
| Tobramycin-Dexamethasone | 117 | $8,920 | $76 |
| Xiidra | 13 | $7,610 | $585 |
| Erythromycin | 278 | $3,390 | $12 |
| Doxycycline Hyclate | 78 | $1,746 | $22 |
| Neomycin-Polymyxin-Dexameth | 82 | $1,283 | $16 |
| Olopatadine | 14 | $951 | $68 |
| Fluticasone Propionate | 37 | $742 | $20 |
| Polymyxin B Sul-Trimethoprim | 19 | $136 | $7 |
| Hydrocodone-Acetaminophen | 15 | $115 | $8 |
2020: 7 drugs
| Tobramycin-Dexamethasone | 102 | $8,390 | $82 |
| Tobradex | 18 | $4,289 | $238 |
| Erythromycin | 224 | $2,709 | $12 |
| Neomycin-Polymyxin-Dexameth | 49 | $791 | $16 |
| Doxycycline Hyclate | 45 | $707 | $16 |
| Fluticasone Propionate | 42 | $599 | $14 |
| Hydrocodone-Acetaminophen | 24 | $142 | $6 |
2019: 10 drugs
| Restasis | 11 | $12,450 | $1,132 |
| Tobramycin-Dexamethasone | 133 | $10,923 | $82 |
| Tobradex | 27 | $6,375 | $236 |
| Erythromycin | 204 | $2,444 | $12 |
| Olopatadine | 16 | $2,050 | $128 |
| Doxycycline Hyclate | 36 | $955 | $27 |
| Fluticasone Propionate | 57 | $796 | $14 |
| Neomycin-Polymyxin-Dexameth | 48 | $748 | $16 |
| Montelukast | 14 | $252 | $18 |
| Hydrocodone-Acetaminophen | 35 | $169 | $5 |
2018: 11 drugs
| Tobramycin-Dexamethasone | 156 | $12,051 | $77 |
| Restasis | 12 | $10,640 | $887 |
| Olopatadine | 25 | $3,375 | $135 |
| Lotemax | 12 | $2,920 | $243 |
| Doxycycline Hyclate | 69 | $2,512 | $36 |
| Mometasone Furoate | 18 | $1,624 | $90 |
| Erythromycin | 144 | $1,472 | $10 |
| Neomycin-Polymyxin-Dexameth | 86 | $1,359 | $16 |
| Fluticasone Propionate | 22 | $419 | $19 |
| Gentak | 15 | $220 | $15 |
| Hydrocodone-Acetaminophen | 27 | $170 | $6 |
2017: 13 drugs
| Tobramycin-Dexamethasone | 134 | $10,920 | $81 |
| Restasis | 13 | $8,642 | $665 |
| Pataday | 29 | $7,787 | $269 |
| Lotemax | 12 | $2,658 | $221 |
| Gentak | 150 | $2,031 | $14 |
| Mometasone Furoate | 11 | $1,787 | $162 |
| Neomycin-Polymyxin-Dexameth | 107 | $1,672 | $16 |
| Doxycycline Hyclate | 30 | $843 | $28 |
| Hydrocodone-Acetaminophen | 144 | $680 | $5 |
| Fluticasone Propionate | 19 | $340 | $18 |
| Erythromycin | 29 | $316 | $11 |
| Montelukast | 11 | $230 | $21 |
| Doxycycline Monohydrate | 12 | $157 | $13 |
2016: 15 drugs
| Pataday | 70 | $13,445 | $192 |
| Tobramycin-Dexamethasone | 98 | $8,345 | $85 |
| Restasis | 12 | $7,724 | $644 |
| Mometasone Furoate | 16 | $2,990 | $187 |
| Nasonex | 12 | $2,914 | $243 |
| Lotemax | 14 | $2,699 | $193 |
| Gentak | 198 | $2,656 | $13 |
| Neomycin-Polymyxin-Dexameth | 92 | $1,608 | $17 |
| Doxycycline Hyclate | 38 | $1,568 | $41 |
| Hydrocodone-Acetaminophen | 228 | $1,552 | $7 |
| Montelukast | 15 | $377 | $25 |
| Gentamicin Sulfate | 20 | $274 | $14 |
| Fluticasone Propionate | 17 | $178 | $10 |
| Erythromycin | 17 | $163 | $10 |
| Polymyxin B Sul-Trimethoprim | 12 | $119 | $10 |
2015: 13 drugs
| Pataday | 109 | $22,910 | $210 |
| Tobramycin-Dexamethasone | 110 | $9,225 | $84 |
| Restasis | 11 | $6,750 | $614 |
| Nasonex | 26 | $5,340 | $205 |
| Lotemax | 27 | $5,333 | $198 |
| Gentak | 164 | $2,400 | $15 |
| Hydrocodone-Acetaminophen | 208 | $1,224 | $6 |
| Doxycycline Monohydrate | 40 | $1,176 | $29 |
| Doxycycline Hyclate | 20 | $903 | $45 |
| Neomycin-Polymyxin-Dexameth | 53 | $895 | $17 |
| Erythromycin | 39 | $507 | $13 |
| Montelukast | 21 | $424 | $20 |
| Gentamicin Sulfate | 34 | $403 | $12 |
2014: 12 drugs
| Pataday | 115 | $23,631 | $205 |
| Tobramycin-Dexamethasone | 108 | $10,162 | $94 |
| Nasonex | 30 | $5,133 | $171 |
| Lotemax | 14 | $2,602 | $186 |
| Gentak | 138 | $2,131 | $15 |
| Doxycycline Monohydrate | 45 | $2,060 | $46 |
| Neomycin-Polymyxin-Dexameth | 87 | $1,540 | $18 |
| Hydrocodone-Acetaminophen | 214 | $1,279 | $6 |
| Doxycycline Hyclate | 15 | $1,092 | $73 |
| Montelukast | 13 | $745 | $57 |
| Erythromycin | 30 | $446 | $15 |
| Gentamicin Sulfate | 39 | $441 | $11 |
2013: 10 drugs
| Tobradex | 90 | $14,807 | $165 |
| Pataday | 84 | $14,768 | $176 |
| Tobramycin-Dexamethasone | 98 | $9,150 | $93 |
| Nasonex | 20 | $2,790 | $139 |
| Doxycycline Monohydrate | 35 | $1,943 | $56 |
| Hydrocodone-Acetaminophen | 228 | $1,634 | $7 |
| Doxycycline Hyclate | 20 | $1,480 | $74 |
| Gentak | 58 | $920 | $16 |
| Neomycin-Polymyxin-Dexameth | 32 | $592 | $19 |
| Erythromycin | 19 | $312 | $16 |
Money from drug and device companies
$416 in 2025
| 2025 | 3 | 7 | None | $416 |
| 2024 | 1 | 5 | None | $244 |
| 2023 | 2 | 5 | None | $116 |
| 2022 | 2 | 2 | None | $63 |
| 2021 | 1 | 1 | None | $43 |
| 2019 | 2 | 3 | None | $199 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotissue Holdings | None | $216 | 2 payments
|
| Amgen | Tepezza | $111 | 4 payments
|
| Argenx US | None | $89 | 1 payment
|
See all 7 published payments
| Amgen | Meals · 2025-10-29 | Tepezza | $28 |
| Biotissue Holdings | Meals · 2025-10-20 | None | $57 |
| Biotissue Holdings | Meals · 2025-10-17 | None | $159 |
| Argenx US | Meals · 2025-10-15 | None | $89 |
| Amgen | Meals · 2025-07-29 | Tepezza | $28 |
| Amgen | Meals · 2025-03-20 | Tepezza | $26 |
| Amgen | Meals · 2025-01-31 | Tepezza | $29 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $244
| Amgen | Tepezza | $244 | 5 payments
|
2023: $116
| Horizon Therapeutics plc | Tepezza | $69 | 4 payments
|
| Bausch & Lomb Americas | Envista Mx60 Iol | $47 | 1 payment
|
2022: $63
| BioTissue Holdings | Prokera | $50 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $13 | 1 payment
|
2021: $43
| Tissuetech | Prokera | $43 | 1 payment
|
2019: $199
| Galderma Laboratories L.P. | None | $108 | 1 payment
|
| TissueTech | Prokera | $91 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ARGENX US, INC. · A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod Ph20 Sc Administered By Prefilled Syringe (Pfs) in Adult Participants With Active Thyroid Eye Disease · 2025 | Their institution | $6,244 |
Checkups this office reported
9 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 99.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 80%That's most of the people this applied to. | 1,332 |
| Breast cancer screeningEligible women who got a mammogram | 94%That's most of the people this applied to. | 1,048 |
| Checked for fall riskOlder patients screened for fall risk | 95%That's most of the people this applied to. | 1,508 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 100%That's most of the people this applied to. | 51 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 0%That's few of the people this applied to. Better on this measure. | 51 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 3,807 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 94%That's most of the people this applied to. | 3,000 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 2,258 |
See the other 1 measures
| Support Electronic Referral Loops By Sending Health InformationAs Medicare defines this measure | 47% | 3,647 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Collects patient feedback
- COVID-19 Vaccine Achievement for Practice Staff
- Did a security review of patient data
- Drug Cost Transparency
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Implementation of a Personal Protective Equipment (PPE) Plan
- Implementation of Use of Specialist Reports Back to Referring Clinician or Group to Close Referral Loop
- Offers telehealth visits
- ONC-ACB Surveillance Attestation
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Provide Education Opportunities for New Clinicians
- Reports cases to public health electronically
- Reports to a public-health or clinical registry
- Exempt from immunization registry reporting
Professional record
- NPI
- 1790758209
- Licence
- CA G45822California G45822: Current · expires 2028-10-31
- Trained
- Northwestern University Feinberg Medical School, 1980
- Group
- North Bay Eye Associates, A Medical Corporation · Eye Care Center of Napa Valley A Medical Corporation
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 1790758209
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0200X (207WX0200X)
- Mailing address
- 400 29th St, Suite 315, Oakland, CA, 94609
- NPI first listed
- 2006-02-07
- NPI last updated
- 2023-10-27
- NPI record certified
- 2023-10-15
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.